July 15, 2021 -- The U.S. National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced it has received $153 million in new funding from the National Institute of Standards and Technology (NIST).
The funding comes in the form of two awards -- one for $70 million to continue operations for an additional five years and one for $83 million for COVID-19 pandemic response projects under the American Rescue Plan (ARP).
U.S. Commerce Secretary Gina Raimondo announced the awards at NIIMBL's recent national meeting in Washington, DC.
NIIMBL was launched in 2017. To date, the institute has more than 180 members in large industry, small-medium size companies, academic institutions, nonprofits, and federal agency partners. NIIMBL has led more than 70 large-scale biopharmaceutical manufacturing innovation projects over the past five years.